115 related articles for article (PubMed ID: 1601759)
1. Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects.
Meyer BH; Muller FO; Luus HG; Drees B; Röthig HJ; Badian M; Eckert HG
J Antimicrob Chemother; 1992 Apr; 29 Suppl A():63-70. PubMed ID: 1601759
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects.
Barbhaiya RH; Knupp CA; Tenney J; Martin RR; Weidler DJ; Pittman KA
J Clin Pharmacol; 1990 Oct; 30(10):900-10. PubMed ID: 2229450
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerance and pharmacokinetics of 2.0 g cefpirome (HR 810) after single and multiple dosing.
Badian M; Malerczyk V; Collins JD; Dixon GT; Verho M; Eckert HG
Chemotherapy; 1988; 34(5):367-73. PubMed ID: 3180904
[TBL] [Abstract][Full Text] [Related]
4. Single- and multiple-dose pharmacokinetics of intravenous cefpirome (HR810) to healthy volunteers.
Nakayama I; Akieda Y; Yamaji E; Nitta Y; Ohishi M; Katagiri K; Imamura N; Takase K
J Clin Pharmacol; 1992 Mar; 32(3):256-66. PubMed ID: 1564130
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and dogs.
Isert D; Klesel N; Limbert M; Markus A; Seibert G; Schrinner E
J Antimicrob Chemother; 1992 Apr; 29 Suppl A():31-7. PubMed ID: 1601754
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects.
Barbhaiya RH; Forgue ST; Gleason CR; Knupp CA; Pittman KA; Weidler DJ; Movahhed H; Tenney J; Martin RR
Antimicrob Agents Chemother; 1992 Mar; 36(3):552-7. PubMed ID: 1622165
[TBL] [Abstract][Full Text] [Related]
7. Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative.
Malerczyk V; Maass L; Verho M; Hajdú P; Klesel N; Rangoonwala R
Infection; 1987; 15(3):211-4. PubMed ID: 3610330
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cefpirome (HR 810), a new cephalosporin derivative administered intramuscularly and intravenously to healthy volunteers.
Maass L; Malerczyk V; Verho M
Infection; 1987; 15(3):207-10. PubMed ID: 3610329
[TBL] [Abstract][Full Text] [Related]
9. Dose linearity testing of intravenous cefpirome (HR 810), a novel cephalosporin derivate.
Maass L; Malerczyk V; Verho M; Hajdú P; Seeger K; Klesel N
Infection; 1987; 15(3):202-6. PubMed ID: 3610328
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval.
Banyai M; Thalhammer F; El-Menyawi I; Heinz G; Traunmüller F; Siostrzonek P
Clin Pharmacol Ther; 2000 Apr; 67(4):368-72. PubMed ID: 10801245
[TBL] [Abstract][Full Text] [Related]
11. Cefpirome clinical pharmacokinetics.
Strenkoski LC; Nix DE
Clin Pharmacokinet; 1993 Oct; 25(4):263-73. PubMed ID: 8261711
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of multiple-dose cefprozil and comparison with cefaclor.
Barbhaiya RH; Shukla UA; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA
Antimicrob Agents Chemother; 1990 Jun; 34(6):1198-203. PubMed ID: 2393281
[TBL] [Abstract][Full Text] [Related]
13. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing.
Lipman J; Wallis SC; Rickard CM; Fraenkel D
Intensive Care Med; 2001 Feb; 27(2):363-70. PubMed ID: 11396280
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of single-dose BMY-28100, a new oral cephalosporin.
Barbhaiya RH; Gleason CR; Shyu WC; Wilber RB; Martin RR; Pittman KA
Antimicrob Agents Chemother; 1990 Feb; 34(2):202-5. PubMed ID: 2327766
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of cefpirome in pediatric patients.
Nahata MC; Barson WJ; Puri SK
Antimicrob Agents Chemother; 1995 Oct; 39(10):2348-9. PubMed ID: 8619595
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients.
Sauermann R; Delle-Karth G; Marsik C; Steiner I; Zeitlinger M; Mayer-Helm BX; Georgopoulos A; Müller M; Joukhadar C
Antimicrob Agents Chemother; 2005 Feb; 49(2):650-5. PubMed ID: 15673747
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of cefpirome in critically ill patients with renal failure treated by continuous veno-venous hemofiltration.
Van der Werf TS; Fijen JW; Van de Merbel NC; Spanjersberg R; Möller AV; Ligtenberg JJ; Tulleken JE; Zijlstra JG; Stegeman CA
Intensive Care Med; 1999 Dec; 25(12):1427-31. PubMed ID: 10660852
[TBL] [Abstract][Full Text] [Related]
18. High extracellular levels of cefpirome in unaffected and infected lung tissue of patients.
Lindenmann J; Kugler SA; Matzi V; Porubsky C; Maier A; Dittrich P; Graninger W; Smolle-Jüttner FM; Joukhadar C
J Antimicrob Chemother; 2011 Jan; 66(1):160-4. PubMed ID: 21081546
[TBL] [Abstract][Full Text] [Related]
19. Single-dose pharmacokinetics of cefpirome in patients with renal impairment.
Lameire N; Malerczyk V; Drees B; Lehr K; Rosenkranz B
Clin Pharmacol Ther; 1992 Jul; 52(1):24-30. PubMed ID: 1623690
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of DQ-2556, a new parenteral 3-quaternary ammonium cephalosporin antibiotic.
Nakashima M; Uematsu T; Kanamaru M; Mizuno A; Matsubayashi K; Okazaki O; Hashimoto S; Hakusui H; Osada Y
J Clin Pharmacol; 1993 Jan; 33(1):57-62. PubMed ID: 8429115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
